Eisai Limited

7 trials 2 recruiting Commercial sponsor

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

2 Recruiting

5 Completed trials

7 Countries active

11 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 2 Phase II: 2 Phase I/II: 3

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Hepatocellular carcinoma 2 Endometrial cancer 2 Colorectal cancer 2 Prodromal Alzheimer's disease 1 Breast cancer metastatic 1 Ovarian cancer 1 Epilepsy 1 Non-small cell lung cancer 1 Triple negative breast cancer 1 HER2 positive breast cancer 1

Top IMPs

LENVATINIB 3 (6S,9AS)-8-((6-(3-(4-ETHYL-1-PIPERAZINYL)-1-AZETIDINYL)-2-PYRIDINYL)METHYL)-6-((2-FLUORO-4-HYDROXYPHENYL)METHYL)HEXAHYDRO-4,7-DIOXO-N-(PHENYLMETHYL)-2-(2-PROPEN-1-YL)-2H-PYRAZINO(2,1-C)(1,2,4)TRIAZINE-1(6H)-CARBOXAMIDE 2 DOXORUBICIN HYDROCHLORIDE 1 FARLETUZUMAB ECTERIBULIN 1 FLORQUINITAU (18F) 1 FLUTAFURANOL (18F) 1 HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 CONJUGATED TO ERIBULIN 1 LECANEMAB 1 PACLITAXEL 1 PEMBROLIZUMAB 1 PERAMPANEL 1

All trials

7 total

A Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors Recruiting

2023-510275-64-00 Phase I/II 4 countries (6S,9AS)-8-((6-(3-(4-ETHYL-1-PIPERAZINYL)-1-AZETIDINYL)-2-PYRIDINYL)METHYL)-6-((…
A study to evaluate efficacy and safety of perampanel when administered together with other current antiepileptic medications in children wi… Recruiting

2023-507794-17-00 Phase II 4 countries PERAMPANEL
An Open-Label Phase 1/2 Trial to Evaluate the Safety, Tolerability, and Efficacy of MORAb 202 in Subjects with Selected Tumor Types. Ended

2023-506868-14-00 Phase I/II 2 countries FARLETUZUMAB ECTERIBULIN; LENVATINIB
AHEAD 3-45 Study: A Clinical Study to Investigate the Effects of BAN2401 in Subjects With Preclinical Alzheimer’s Disease Ended

2024-510888-39-00 Phase III 1 country FLORQUINITAU (18F); FLUTAFURANOL (18F)
A Phase 3 clinical study to investigate the effects of BAN2401 in patients with Early Alzheimer's Disease. Ended

2024-510887-22-00 Phase III 5 countries LECANEMAB
Phase 2 Study of BB-1701 in HER2 positive or HER2-low metastatic breast cancer Ended

2023-506866-30-00 Phase II 3 countries HUMANISED IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST RECEPTOR TYROSINE-PROTEIN KINAS…
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors Ended

2023-505425-14-00 Phase I/II 1 country (6S,9AS)-8-((6-(3-(4-ETHYL-1-PIPERAZINYL)-1-AZETIDINYL)-2-PYRIDINYL)METHYL)-6-((…

Showing 1–7 of 7 trials

← All sponsors A–Z